Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · October 08, 2022

Overactive EGFR Signaling in Pachyonychia Congenita and Treatment With Oral Erlotinib

Journal of Investigative Dermatology

 

Additional Info

Journal of Investigative Dermatology
EGFR signaling is overactive in Pachyonychia congenita: effective treatment with oral erlotinib
J Invest Dermatol 2022 Sep 15;[EPub Ahead of Print], J Basset, L Marchal, A Hovnanian

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading